Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.

Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X

Open source

DOI: 10.1212/wnl.0000000000010376
Published: 2020 Sep 29
Container: Neurology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1212/wnl.0000000000010376,
  title = {Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.},
  author = {Hauser SL and Kappos L and Arnold DL and Bar-Or A and Brochet B and Naismith RT and Traboulsee A and Wolinsky JS and Belachew S and Koendgen H and Levesque V and Manfrini M and Model F and Hubeaux S and Mehta L and Montalban X},
  year = {2020},
  journal = {Neurology},
  doi = {10.1212/wnl.0000000000010376},
  url = {https://doi.org/10.1212/wnl.0000000000010376}
}

RIS

TY  - JOUR
TI  - Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
AU  - Hauser SL
AU  - Kappos L
AU  - Arnold DL
AU  - Bar-Or A
AU  - Brochet B
AU  - Naismith RT
AU  - Traboulsee A
AU  - Wolinsky JS
AU  - Belachew S
AU  - Koendgen H
AU  - Levesque V
AU  - Manfrini M
AU  - Model F
AU  - Hubeaux S
AU  - Mehta L
AU  - Montalban X
PY  - 2020
JO  - Neurology
DO  - 10.1212/wnl.0000000000010376
UR  - https://doi.org/10.1212/wnl.0000000000010376
ER  -

APA

SL, H., L, K., DL, A., A, B., B, B., RT, N., A, T., JS, W., S, B., H, K., V, L., M, M., F, M., S, H., L, M., & X, M. (2020). Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.. Neurology. https://doi.org/10.1212/wnl.0000000000010376

Source records

pubmed · retrieved 2026-11-10T23:59:17.761Z